(RXRX) Recursion Pharmaceuticals - Overview
Stock: REC-994, REC-2282, REC-4881, REC-3964, RBM39
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 91.4% |
| Relative Tail Risk | -8.42% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.27 |
| Alpha | -81.62 |
| Character TTM | |
|---|---|
| Beta | 2.406 |
| Beta Downside | 2.227 |
| Drawdowns 3y | |
|---|---|
| Max DD | 77.55% |
| CAGR/Max DD | -0.28 |
Description: RXRX Recursion Pharmaceuticals January 13, 2026
Recursion Pharmaceuticals (NASDAQ:RXRX) is a clinical-stage biotech that combines high-throughput biology, chemistry, automation, and data-science to “industrialize” drug discovery, focusing on rare-disease and oncology targets.
Its current pipeline includes five late-stage candidates: REC-994 (Phase 2 for cerebral cavernous malformation), REC-2282 (Phase 2/3 for neurofibromatosis type 2, an FDA-orphan-designated program), REC-4881 (Phase 1b/2 for familial adenomatous polyposis and also in Phase 2 for AXIN1/APC-mutant cancers), REC-3964 (Phase 1 for Clostridioides difficile infection), and a pre-clinical RBM39 program aimed at HR-proficient ovarian cancer.
Strategic collaborations span Bayer, Roche & Genentech, Takeda, the University of Utah Research Foundation, and the Ohio State Innovation Foundation, providing both validation of the platform and potential co-development funding.
Key financial metrics (as of Q4 2023) show a cash runway of roughly $210 million, a quarterly R&D spend of $68 million (≈ 30 % of total expenses), and a market capitalization near $1.1 billion, indicating sufficient liquidity to advance its pipeline through 2025 under current burn rates.
Sector-level drivers that materially affect Recursion include the accelerating adoption of AI-enabled drug discovery (which the industry estimates can cut lead-time by 30-50 %), robust venture and public-market funding for biotech (U.S. biotech IPO activity rose 22 % YoY in 2023), and a regulatory climate that increasingly grants orphan-drug incentives for rare-disease indications.
For a deeper quantitative view, you may want to explore ValueRay’s detailed analytics on RXRX.
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income: -715.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.32 > 0.02 and ΔFCF/TA 14.19 > 1.0 |
| NWC/Revenue: 1284 % < 20% (prev 565.4%; Δ 718.6% < -1%) |
| CFO/TA -0.32 > 3% & CFO -441.2m > Net Income -715.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.60 > 1.5 & < 3 |
| Outstanding Shares: last quarter (447.0m) vs 12m ago 58.18% < -2% |
| Gross Margin: -93.82% > 18% (prev 0.34%; Δ -9416 % > 0.5%) |
| Asset Turnover: 4.10% > 50% (prev 8.89%; Δ -4.80% > 0%) |
| Interest Coverage Ratio: -294.4 > 6 (EBITDA TTM -636.9m / Interest Expense TTM 2.43m) |
Altman Z'' -12.24
| A: 0.40 (Total Current Assets 714.1m - Total Current Liabilities 155.1m) / Total Assets 1.40b |
| B: -1.41 (Retained Earnings -1.97b / Total Assets 1.40b) |
| C: -0.67 (EBIT TTM -714.1m / Avg Total Assets 1.06b) |
| D: -5.48 (Book Value of Equity -1.93b / Total Liabilities 352.6m) |
| Altman-Z'' Score: -12.24 = D |
Beneish M 1.00
| DSRI: 14.42 (Receivables 21.9m/2.25m, Revenue 43.5m/64.6m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 2.81 (AQ_t 0.36 / AQ_t-1 0.13) |
| SGI: 0.67 (Revenue 43.5m / 64.6m) |
| TATA: -0.20 (NI -715.5m - CFO -441.2m) / TA 1.40b) |
| Beneish M-Score: 8.65 (Cap -4..+1) = D |
What is the price of RXRX shares?
Over the past week, the price has changed by -5.01%, over one month by -12.53%, over three months by -13.85% and over the past year by -45.03%.
Is RXRX a buy, sell or hold?
- StrongBuy: 1
- Buy: 1
- Hold: 6
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the RXRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 7 | 75.9% |
| Analysts Target Price | 7 | 75.9% |
| ValueRay Target Price | 3.3 | -17.6% |
RXRX Fundamental Data Overview February 03, 2026
P/B = 2.0755
Revenue TTM = 43.5m USD
EBIT TTM = -714.1m USD
EBITDA TTM = -636.9m USD
Long Term Debt = 11.9m USD (from longTermDebt, last quarter)
Short Term Debt = 20.4m USD (from shortTermDebt, last quarter)
Debt = 82.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -577.5m USD (from netDebt column, last quarter)
Enterprise Value = 1.61b USD (2.18b + Debt 82.4m - CCE 659.8m)
Interest Coverage Ratio = -294.4 (Ebit TTM -714.1m / Interest Expense TTM 2.43m)
EV/FCF = -3.59x (Enterprise Value 1.61b / FCF TTM -448.0m)
FCF Yield = -27.89% (FCF TTM -448.0m / Enterprise Value 1.61b)
FCF Margin = -1029 % (FCF TTM -448.0m / Revenue TTM 43.5m)
Net Margin = -1644 % (Net Income TTM -715.5m / Revenue TTM 43.5m)
Gross Margin = -93.82% ((Revenue TTM 43.5m - Cost of Revenue TTM 84.4m) / Revenue TTM)
Gross Margin QoQ = none% (prev -5.54%)
Tobins Q-Ratio = 1.15 (Enterprise Value 1.61b / Total Assets 1.40b)
Interest Expense / Debt = 1.01% (Interest Expense 833.0k / Debt 82.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -564.1m (EBIT -714.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.60 (Total Current Assets 714.1m / Total Current Liabilities 155.1m)
Debt / Equity = 0.08 (Debt 82.4m / totalStockholderEquity, last quarter 1.05b)
Debt / EBITDA = 0.91 (negative EBITDA) (Net Debt -577.5m / EBITDA -636.9m)
Debt / FCF = 1.29 (negative FCF - burning cash) (Net Debt -577.5m / FCF TTM -448.0m)
Total Stockholder Equity = 983.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -67.31% (Net Income -715.5m / Total Assets 1.40b)
RoE = -72.74% (Net Income TTM -715.5m / Total Stockholder Equity 983.7m)
RoCE = -71.72% (EBIT -714.1m / Capital Employed (Equity 983.7m + L.T.Debt 11.9m))
RoIC = -55.98% (negative operating profit) (NOPAT -564.1m / Invested Capital 1.01b)
WACC = 14.27% (E(2.18b)/V(2.27b) * Re(14.78%) + D(82.4m)/V(2.27b) * Rd(1.01%) * (1-Tc(0.21)))
Discount Rate = 14.78% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 38.46%
Fair Price DCF = unknown (Cash Flow -448.0m)
EPS Correlation: 12.67 | EPS CAGR: 26.11% | SUE: 4.0 | # QB: 1
Revenue Correlation: 36.61 | Revenue CAGR: 21.41% | SUE: -3.17 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.32 | Chg30d=+0.043 | Revisions Net=-1 | Analysts=5
EPS next Year (2026-12-31): EPS=-1.17 | Chg30d=+0.082 | Revisions Net=+3 | Growth EPS=+27.0% | Growth Revenue=+34.2%